A Study Testing a Two-Session Partner Navigation Program to Help Young Adults Who Inject Drugs Start Hepatitis C Treatment
Led by University of California, San Francisco · Updated on 2025-03-13
500
Participants Needed
1
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a behavioral intervention called the Partner Navigation Intervention to increase hepatitis C HCV treatment initiation among adults who inject drugs. This randomized controlled trial focuses on people who inject drugs PWID with recently diagnosed HCV, enrolling 250 adult participants along with their primary injecting partners. The study particularly targets young adults between 18 and 30 years old to understand how partner support can impact treatment start rates.
Participants will be randomly assigned to either the intervention group or the standard care group. Those in the intervention group receive two counseling sessions the first session occurs immediately after HCV results disclosure, focusing on setting treatment goals and engaging the injecting partner to support treatment initiation. The second session, one week later, includes both the participant and their partner working together to create a personalized navigation map to guide the treatment process. The control group receives standard HCV results disclosure following the usual counseling protocol.
During the study, researchers will monitor participants at multiple time points up to 24 months after HCV results disclosure, assessing outcomes such as treatment initiation, partner support changes, treatment completion, and sustained virologic response. Participants will be evaluated through counseling sessions, interviews, and follow-up assessments. The study aims to understand the effectiveness and mechanism of this behavioral intervention in helping PWID start and complete HCV treatment, with ongoing safety monitoring throughout the trial period.
CONDITIONS
Brief Title
Partner Navigation Intervention for Hepatitis C Treatment Among Young People Who Inject Drugs
Research Team
M
Meghan D Morris, MPH, PhD
C
Claire McDonell, MS
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
Partner Navigation Intervention
Standard of Care (No Intervention)
Contemporary Linkage‑to‑Care Model
What it is
A two‑session, disclosure counselor‑led behavioral intervention where an injecting partner helps support and navigate the person with HCV treatment
Usual care without structured behavioral navigation support
Standard linkage‑to‑care models used in practice, such as simplified patient navigation or integrated care approaches for PWID with HCV
Primary use
To increase initiation of HCV treatment among PWID by using their injecting partner as a support and navigation aid
Reflects usual treatment initiation pathway without additional structured support
Facilitating HCV treatment initiation through structured care coordination or patient navigation in clinical settings
Evidence status
Efficacy under evaluation in this randomized trial; mechanism being studied
Not tested in this trial but reflects routine practice where effectiveness varies
Linked models such as patient navigation or integrated care have shown improved linkage to treatment among PWID in other studies
Important limitations
Effectiveness depends on the availability and engagement of a primary injecting partner, which may limit applicability
No additional behavioral support may limit initiation of HCV treatment among marginalized populations
Implementation may vary by setting and access to peer navigators or integrated services
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
Adults aged 18 years or older
Self-report injecting drugs in the past month
Self-report having a primary injecting partner who currently injects drugs together
Hepatitis C infection identified at a partnering community-based clinical site
You will not qualify if you...
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Behavioral Intervention
Duration - 1 week
Participants in the intervention group attend two counseling sessions to support and navigate HCV treatment initiation with their injecting partner.
2 visits (in-person)
Follow-up Monitoring
Duration - Up to 3 years
Participants are monitored for treatment initiation, partner support changes, treatment completion, and sustained virologic response over several months to years.
Assessments at 1 week, 1 month, 3 months, 6 months, 12 months, 24 months, and up to 3 years after HCV infection disclosure visit
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
HEALTH_SERVICES_RESEARCH
Number of Arms
2
Similar Trials
Acceptability Study of Rapid Screening for Hepatitis B, C, and HIV in Drug Users at Non-traditional Community Sites Using TROD and FibroScan
Establishing a Biorepository for Liver Disease Research Including Hepatitis C and NASH at University at Buffalo
Blood Sample Collection to Study DNA Methylation Markers for Detecting Cancer and Benign Diseases in Adults
Enhancing Hepatitis C Treatment in Opioid Substitution Clinics ETHOS II Partnership for Improved Care in Drug and Alcohol Services
Clinical Evaluation and Long-Term Follow-up Study of Patients With Acute and Chronic Liver Diseases Including Genetic Analysis
Study of Hepatitis C Treatment With Glecaprevir-Pibrentasvir in Pregnant Women With Past or Current Drug Use
Study of Liver Disease and Its Impact on Other Body Diseases
Using Data From Buddhist Tzu Chi Medical Foundation
A Study Testing a Two-Session Partner Navigation Program to Help Young Adults Who Inject Drugs Start Hepatitis C Treatment
Testing Practice Coaching to Improve On-site HIV and Hepatitis C Testing in Opioid Treatment Programs
A Study Comparing Two Coaching Approaches and an Information Control
Proteogenomic Monitoring to Detect Early Kidney Disease, Rejection, and Hepatitis C in Liver Transplant Patients
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
A single-site randomized controlled trial of partner navigation to HCV treatment for people who inject drugs: a study protocol for the You're Empowered for Treatment Initiation (YETI) partner trial.